Full-Time

Associate Director

E2E Supply Chain Product Planner

Posted on 4/16/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

Norwood, MA, USA

May telecommute up to two (2) days per week.

Category
Supply Chain Management
Operations & Logistics
Required Skills
Supply Chain Management
SAP Products
Requirements
  • Requires a Bachelor’s degree, or foreign equivalent, in Industrial Engineering, Supply Chain Management, or related field and eight (8) years of progressive, post-baccalaureate experience as a Supply Chain Planner, Industrial Engineer, Production/Logistics Planning Coordinator, or related position.
  • Alternatively, employer will accept a Master’s degree in fields specified and six (6) years of experience in the stated occupations.
  • Must have 6 years of experience with: SAP ERP and SCM Advanced Planning Systems; Logistics distribution processes and quality systems applied to supply planning; Regulatory and lifecycle management applied to supply planning; Supply chain support for pharmaceutical drug substance and product manufacturing processes; End-to-end supply scenario planning and presentations to management; Gaining cross-functional alignment on global product supply plans.
Responsibilities
  • Develop and maintain the E2E (end-to-end) Product Supply Strategy (including inventory, sourcing strategies, logistics and business continuity) for assigned product/product family.
  • Support the strategic decisions across functional and business units regarding demand and supply balancing, inventory management for product, long range planning and the implementation of lifecycle changes into the supply chain through S&OP (Sales & Operations) and S&OE (Sales & Operations Executions) forums.
  • Support the implementation of supply strategies for specified product to optimize performance of the value chain by managing complexity and influencing across the company’s ecosystem.
  • Balance product supply volumes versus customer demand according to most recent commercial demand consensus forecasts and supply network capabilities.
  • Perform inventory management according to financial targets and supply risk mitigation strategies.
  • Act as point person for scenario planning for the product, to assist in driving short- to mid-range plans and capacity analyses, and make supply response proposals to balance capacities.
  • Lead all scenario planning activities for designated product by assessing all production requirements across E2E supply network, accounting for the regulatory approved filing strategy, site selection strategies, contract and strategic commitments by production site, and other considerations.
  • Proactively identify supply risks and present options for decision making.
  • Ensure supply planning and delivery plans take into consideration minimum shelf-life requirements according to customer expectations.
  • Develop plans and contingencies for ensuring stable supply for the introduction of new products and/or implementation of product lifecycle changes.
  • Maintain accurate data flowing into planning systems in close collaboration with various Cross-functional teams (Commercial, Project, Master Data, Manufacturing and Supply Chain teams).
  • Contribute and participate in the monthly reviews of Key Performance Indicators and required actions to improve.
  • Optimize inventory costs by planning adequate inventory levels which minimize risks of supply disruptions while ensuring optimal usage of financial resources.
  • Drive key issue resolution including cost/benefit analysis to find optimal solutions to supply partners.
  • Support leadership with preparation of monthly S&OP business process for short- and long-term decisions around supply, demand and finance balancing, as well as with reports and ad-hoc assessments.
  • Participate in key enterprise projects such as implementation of ERP (Enterprise Resource Planning) and Advanced Planning Systems with the intent to automate and manage core Supply Chain Management processes.
  • Support implementation of system improvements, including both ad-hoc modeling requirements and enterprise-wide rollouts.
  • Working cross-functionally, influence and monitor supply and demand plans in the operational, tactical and long-range time horizons, incorporating the latest launch and regulatory timelines, activities at each manufacturing site, and customer/local requirements.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in the process of making proteins in the body. Their products work by providing cells with the instructions needed to produce specific proteins that can help treat diseases. This approach allows for a new category of medicines that could change how drugs are discovered, developed, and manufactured. Unlike traditional pharmaceuticals, which often rely on chemical compounds, Moderna's use of mRNA offers a different method of treatment that has the potential to be more effective. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create advanced therapies.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's RSV vaccine received approval in Australia and the UK in 2025.
  • The company is collaborating with Merck on a personalized cancer vaccine for 2027.
  • Moderna's late-stage pipeline shows strong momentum with multiple product approvals expected.

What critics are saying

  • Patent litigation with Pfizer and BioNTech could impact Moderna's financials.
  • HHS review of bird flu vaccine contract may affect revenue projections.
  • Moderna reported a significant net loss in 2024, affecting investor confidence.

What makes Moderna unique

  • Moderna is pioneering mRNA technology as a new class of medicines.
  • mRNA technology allows for rapid development and manufacturing of vaccines.
  • Moderna's mRNA platform is versatile, targeting infectious and non-infectious diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

5%
Notas de Prensa
Apr 7th, 2025
Moderna to showcase its extensive research on Infectious Diseases at ESCMID 2025.

Moderna, Inc. (NASDAQ:MRNA) announces that it will present at the World Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which will be held in Vienna, Austria, from April 11 to 15, 2025, its research in multiple areas of infectious diseases, such as COVID-19, influenza, respiratory syncytial virus, cytomegalovirus, norovirus, and mpox.

PharmiWeb
Mar 31st, 2025
Moderna Receives Australian Therapeutic Goods Administration Approval For Rsv Vaccine For Older Adults

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19."We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.About mRESVIA (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells

PharmiWeb
Mar 28th, 2025
Moderna Receives Medicines And Healthcare Products Regulatory Agency Marketing Authorization In The Uk For Rsv Vaccine

mRESVIA® is Moderna's second approved product in the UKCAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older."The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i]"Given the serious consequences of RSV for older people, which can lead to hospitalization and severe outcomes, we are delighted that the MHRA has authorized our RSV vaccine," said Darius Hughes, UK General Manager of Moderna. "With the MHRA decision, mRESVIA becomes Moderna's second approved product in the UK, further demonstrating the role of mRNA vaccines in helping to protect the public from respiratory diseases."The approval is based on positive data from the Phase 3 clinical trial ConquerRSV , a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries. No serious safety concerns were identified in the Phase 3 trial.About mRNA-1345 (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein

Bioversity International
Mar 27th, 2025
Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) Launch New Biomanufacturing Training Program in Collaboration with Moderna

Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) launch new biomanufacturing training program in collaboration with Moderna.

Assure Test
Mar 7th, 2025
Pfizer & BioNTech vs. Moderna: COVID-19 Vaccine Patent Lawsuit

The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.